Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Silo Pharma (SILO) EPS (Weighted Average and Diluted) (2019 - 2025)

Silo Pharma (SILO) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.11 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 74.35% to -$0.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.54 through Dec 2025, up 55.74% year-over-year, with the annual reading at -$0.5 for FY2025, 57.98% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.11 in Q4 2025 for Silo Pharma, up from -$0.12 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.2 in Q3 2021 to a low of -$0.58 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.1 across 5 years, with a median of -$0.29 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 32100.0% in 2021 and later tumbled 6402.43% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.47 in 2021, then fell by 23.4% to -$0.58 in 2022, then surged by 34.48% to -$0.38 in 2023, then decreased by 7.89% to -$0.41 in 2024, then soared by 74.35% to -$0.11 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SILO at -$0.11 in Q4 2025, -$0.12 in Q3 2025, and -$0.19 in Q2 2025.